Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Toshiba shareholders oust chairman, in shake-up for Japan Inc

06/25/2021 | 12:13pm EDT
FILE PHOTO: Toshiba Corp CEO Tsunakawa attends a news conference at the company's headquarters in Tokyo

TOKYO (Reuters) - Toshiba Corp shareholders ousted the chairman of the board on Friday, delivering a powerful rebuke to the company after management was found to have colluded with the Japanese government to put pressure on foreign investors.

The unexpected removal of chairman Osamu Nagayama, a veteran of corporate Japan, and another director marked a clear victory for corporate governance, and sent a strong signal about overseas investors' ability to push through change even at one of Japan Inc's most storied conglomerates.

The board said it would undertake a full review of assets and devise a plan to create growth via dividends and buying back shares. It would also engage with potential investors, it said, comments that could spark tension with the government, which regards Toshiba as a strategic asset.

CEO Satoshi Tsunakawa was appointed as interim chairman, the company said, adding it recognised the seriousness of the rejection of the two directors.

"This result is a sign of a paradigm shift in Japan and will only embolden activist investors whether foreign or domestic," said Justin Tang, head of Asian research at United First Partners in Singapore.

Tsunakawa retook the helm in April after Toshiba's previous CEO left, but has said he does not plan to stay for too long. Ousters of board members at Japanese companies, particularly household names such as Toshiba, are extremely rare.

But supporters of Nagayama say his failure to win re-election will only set back Toshiba further, depriving the industrial conglomerate, which has lurched from crisis to crisis since an accounting scandal in 2015, of an experienced leadership.

A breakdown of the vote was not immediately disclosed.

The strategic review will be led by Paul Brough, a chartered account with experience in mergers and acquisitions as a financial adviser.

One Toshiba source, who was not authorised to speak to the media, said foreign investors had voted in greater numbers than in previous shareholder meetings as they saw it as an important test case of corporate governance in Japan.


How the government responds has yet to seen, but so far Trade Minister Hiroshi Kajiyama has been unapologetic about his ministry's dealings with Toshiba, saying the policies it implemented were natural ones for the ministry to take.

Toshiba makes defence equipment and nuclear reactors and is strategically important to the government.

"In general the hope is that corporate governance can be improved through discussions with shareholders and at the same time we work to secure the stable development of businesses and technology that are important from a national security standpoint," he told a regular news conference ahead of the AGM.

On Thursday, Akira Amari, a former economy minister and an influential lawmaker in the ruling Liberal Democratic Party, accused activist investors of focusing only on short-term profits and called for better monitoring of such investors to protect economic security.


Shares in Toshiba closed down 0.6%. The stock has increased by around two-thirds in value this year, bolstered by a $20 billion bid for the company by private equity company CVC Capital. Although Toshiba has dismissed that bid, it has promised the strategic review.

Nagayama's ouster could help activist shareholders push the company to consider take-private offers. Since CVC's bid, event-driven hedge funds have been actively buying Toshiba shares, making the shareholder roster potentially more favourable for activists, investor sources have said.

Nagayama, who was seen as cautious about such offers, only joined Toshiba's board in mid-2020 after the alleged pressuring of foreign shareholders to vote in line with management's board nominees took place.

A former Chugai Pharmaceutical CEO and Sony Group Corp board director, he is well respected and both the electronics giant and former U.S. ambassador to Japan John Roos had expressed their support for him.

But his critics argued he should step down to take responsibility for the board's resistance to address the allegations.

Shareholder advisory firms Institutional Shareholder Services Inc and Glass Lewis had recommended shareholders not reappoint him, while 3D Investment Partners, Toshiba's Singapore-based No. 2 shareholder with a 7.2% stake, had called for his resignation.

3D Investment said in a statement after the result that it hoped the AGM marked the beginning of a new era and it looked forward to constructive, ongoing dialogue with Toshiba's board and management team.

Toshiba nominated 11 directors at the AGM, including Nagayama. Nobuyuki Kobayashi, a member of the audit committee, was also voted out.

(Reporting by Makiko Yamazaki; Additional reporting by Yuki Nitta and Tim Kelly in Tokyo and Anshuman Daga in Singapore; Editing by Edwina Gibbs, David Dolan, Alexander Smith and David Evans)

By Makiko Yamazaki

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. 4.09% 4304 End-of-day quote.-21.79%
MSCI SINGAPORE (GDTR) -0.56% 6540.383 Real-time Quote.13.02%
NITTA CORPORATION 2.00% 2860 End-of-day quote.28.25%
OUSTER, INC. -3.32% 7.29 Delayed Quote.0.00%
SONY GROUP CORPORATION 5.18% 13000 End-of-day quote.26.40%
TOSHIBA CORPORATION 2.19% 4910 End-of-day quote.70.19%
X FINANCIAL -0.23% 4.27 Delayed Quote.113.50%
09/24PRESS RELEASE : Roche presents new data at World -2-
09/22PRESS RELEASE : Roche launches three respiratory test panels on cobas 6800/8800 Systems in..
09/20PRESS RELEASE : New Phase III data support the -2-
09/17PRESS RELEASE : Roche receives positive CHMP -2-
09/15PRESS RELEASE : Roche opens access to pathology imaging tools to improve patient care
09/14PRESS RELEASE : Temedica develops new digital companion Brisa for people with multiple scl..
09/13CHUGAI PHARMACEUTICAL : Script (including Q&A)
09/09PRESS RELEASE : Roche signs definitive share purchase agreement with long-term partner TIB..
09/08Nikkei 225 Up 0.9%, Tops 30,000, Extends Rally on New Government Hopes
09/08Japan's Nikkei ends at near 6-month high on bargain hunting for cheap stocks
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Sales 2021 882 B 7 965 M 7 965 M
Net income 2021 265 B 2 392 M 2 392 M
Net cash 2021 485 B 4 382 M 4 382 M
P/E ratio 2021 26,7x
Yield 2021 1,41%
Capitalization 7 077 B 63 921 M 63 895 M
EV / Sales 2021 7,47x
EV / Sales 2022 7,45x
Nbr of Employees 7 555
Free-Float 37,8%
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | 4519 | JP3519400000 | MarketScreener
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 13
Last Close Price 4 304,00 JPY
Average target price 4 696,92 JPY
Spread / Average Target 9,13%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485